Advertisement

Adjuvante Strahlentherapie beim Mammakarzinom

  • Jürgen DunstEmail author
  • Cordula Petersen
  • Nicolai Maass
Leitthema
  • 10 Downloads

Zusammenfassung

Die Strahlentherapie beim Mammakarzinom hat sich in den letzten Jahren erheblich gewandelt. Die wichtigste Änderung war die Einführung einer moderaten Hypofraktionierung für die Mehrheit der Patientinnen, eine Hypofraktionierung mit moderater Akzelerierung (15–16 Fraktionen, Gesamtdosis ca. 40–42 Gy, Behandlungszeit ca. 3 Wochen). Für günstige Tumoren ist eine Teilbrustbestrahlung möglich. Die adjuvante Bestrahlung der regionalen Lymphknoten kann vermutlich die Prognose für Subgruppen verbessern, doch die optimale Abstimmung der Behandlungsmodalitäten bleibt eine Herausforderung. Für Patientinnen mit linksseitigen Tumoren haben sich herzschonende Verfahren, z. B. Bestrahlung in tiefer Inspiration mit „breath hold“, etabliert.

Schlüsselwörter

Teilbrustbestrahlung Hypofraktionierung Prognose  Rezidiv Lymphknoten 

Adjuvant radiotherapy for breast cancer

Abstract

Adjuvant radiotherapy for breast cancer has undergone significant changes during recent years. The most important modification has been the introduction of moderately hypofractionated radiotherapy for the majority of patients, e.g. a total dose of about 40–42 Gy in 15 or 16 fractions in an overall treatment time of 3 weeks. Partial breast irradiation has become an accepted alternative to whole breast radiotherapy for patients with low-risk tumors. Adjuvant irradiation of regional nodes may improve prognosis in subgroups but the optimal adjustment of treatment modalities remains a challenge. In patients with left-sided tumors, heart-sparing techniques (e.g. deep inspiration breath-hold) have become standard

Keywords

Partial breast irradiation Dose hypofractionation Prognosis Recurrence Lymph nodes 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J. Dunst, C. Petersen und N. Maass geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

Verwendete Literatur

  1. 1.
    Aly MMOM, Abo-Madyan Y, Jahnke L, Wenz F, Glatting G (2016) Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH). Radiat Oncol 11:16CrossRefGoogle Scholar
  2. 2.
    Bantema-Joppe EJ, Vredeveld EJ, de Bock GH, Busz DM, Woltman-van Iersel M, Dolsma WV, van der Laan HP, Langendijk JA, Maduro JH (2013) Five year outcomes of hypofractionated simultaneous integrated boost irradiation in breast conserving therapy; patterns of recurrence. Radiother Oncol 108:269–272CrossRefGoogle Scholar
  3. 3.
    Budach W, Boelke E, Kammers K, Matuschek C, Gerber PA, Nestle-Kraemling C (2015) Adjuvant radiotherapy of regional lymph nodes in breast cancer—a meta-analysis of randomized trials—an update. Radiat Oncol 10:258CrossRefGoogle Scholar
  4. 4.
    Chadha M, Vongtama D, Friedmann P, Parris C, Boolbol SK, Woode R, Harrison LB (2012) Comparative acute toxicity from whole breast irradiation using 3‑week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer 12:57–62CrossRefGoogle Scholar
  5. 5.
    Coles CE, Griffin CL, Kirby AM et al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5‑year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390:1048–1060CrossRefGoogle Scholar
  6. 6.
    Dellas K, Vonthein R, Zimmer J, Dinges S, Boicev AD, Andreas P, Fischer D, Winkler C, Ziegler A, Dunst J, ARO Study Group. (2014) Hypofractionation with simultaneous integrated boost for early breast cancer. Results of the German multicentre phase II trial (ARO-2010-01). Strahlenther Onkol 190:646–653CrossRefGoogle Scholar
  7. 7.
    Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575CrossRefGoogle Scholar
  8. 8.
    Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR, START Trialists’ Group (2013) The UK Standardisation of BreastRadiotherapy (START) trials of radiotherapy hypofractionation for treatment ofearly breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094CrossRefGoogle Scholar
  9. 9.
    Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, Carrie C, Roullet B, Suchaud JP, Teissier E, Lucardi A, Gerard JP, Belot A, Iwaz J, Ecochard R, Romestaing P (2013) Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys 86:860–866CrossRefGoogle Scholar
  10. 10.
    Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, Haviland J, Bentzen SM, Yarnold JR (2006) Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomized trial. Lancet Oncol 7:467–471CrossRefGoogle Scholar
  11. 11.
    Peterson D, Truong PT, Parpia S et al (2015) Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. Int J Radiat Oncol Biol Phys 91:968–976CrossRefGoogle Scholar
  12. 12.
    Poortmans PM, Collette S, Kirkove C et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373:317–327CrossRefGoogle Scholar
  13. 13.
    START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR (2008) The UK Standardization of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9:331–341CrossRefGoogle Scholar
  14. 14.
    START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR (2008) The UK Standardization of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371:1098–1107CrossRefGoogle Scholar
  15. 15.
    Strnad V, Ott OJ, Hildebrandt G, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO) et al (2016) 5‑year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 387(10015):229–238CrossRefGoogle Scholar
  16. 16.
    Thorsen LB, Offersen BV, Dano H et al (2016) DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol 34(4):314–320CrossRefGoogle Scholar
  17. 17.
    Twyman-Saint Victor C, Rech AJ, Maity A et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373–377CrossRefGoogle Scholar
  18. 18.
    Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, Reynders T, Schuermans D, Leysen K, Hanon S, Van Camp G, Vincken W, Storme G, Verellen D, De Ridder M (2012) Short course radiotherapy with simultaneous integrated boost for stage I‑II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol 7:80CrossRefGoogle Scholar
  19. 19.
    Van Parijs H, Reynders T, Heuninckx K, Verellen D, Storme G, De Ridder M (2014) Breast conserving treatment for breast cancer: dosimetric comparison of sequential versus simultaneous integrated photon boost. Biomed Res Int 2014:827475PubMedPubMedCentralGoogle Scholar
  20. 20.
    Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M, TARGIT trialists’ group (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383(9917):603–613.  https://doi.org/10.1016/S0140-6736(13)61950-9 CrossRefGoogle Scholar
  21. 21.
    Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, Luini A, Veronesi P, Galimberti V, Zurrida S, Leonardi MC, Lazzari R, Cattani F, Gentilini O, Intra M, Caldarella P, Ballardini B (2013) Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 14:1269–1277CrossRefGoogle Scholar
  22. 22.
    Whelan T, Olivotto IA, Parulekar WR et al (2015) Regional nodal irradiation in early stage breast cancer. N Engl J Med 373:307–316CrossRefGoogle Scholar

Weiterführende Literatur

  1. 23.
    Budach W, Matuschek C, Bölke E et al (2015) DEGRO practical guidelines for radiotherapy of breast cancer V: therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol 19:623–633CrossRefGoogle Scholar
  2. 24.
    Sautter-Bihl ML, Sedlmayer F, Budach W et al (2014) How nescience may obscure evidence. Strahlenther Onkol 190(10):861–863CrossRefGoogle Scholar
  3. 25.
    Sedlmayer F, Sautter-Bihl ML, Budach W, Dunst J, Fastner G, Feyer P, Fietkau R, Haase W, Harms W, Souchon R, Wenz F, Sauer R, Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) (2013) Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy? Statement of the German and the Austrian Societies of Radiooncology (DEGRO/ÖGRO). Strahlenther Onkol 189:193–196CrossRefGoogle Scholar
  4. 26.
    Sedlmayer F, Sautter-Bihl ML, Budach W, Dunst J, Fastner G, Feyer P, Fietkau R, Haase W, Harms W, Souchon R, Wenz F, Sauer R, Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) (2013) DEGRO practical guidelines: radiotherapy of breast cancer I. Radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol 189:825–833CrossRefGoogle Scholar
  5. 27.
    Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, Perera F, Fyles A, Schneider K, Gulavita S, Freeman C (2010) Longterm results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362:513–520CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Jürgen Dunst
    • 1
    Email author
  • Cordula Petersen
    • 2
  • Nicolai Maass
    • 3
  1. 1.Klinik für StrahlentherapieChristian-Albrechts-Universität zu Kiel, UKSH Campus KielKielDeutschland
  2. 2.Klinik für Strahlentherapie und RadioonkologieUniversitätsklinikum Hamburg-EppendorfHamburgDeutschland
  3. 3.Klinik für FrauenheilkundeChristian-Albrechts-Universität zu Kiel, UKSH Campus KielKielDeutschland

Personalised recommendations